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http://www.ojrd.com/content/8/1/43RESEARCH Open AccessIn vitro and in vivo consequences of variant
medium-chain acyl-CoA dehydrogenase
genotypes
Catharina ML Touw1,2,3*, G Peter A Smit1,3, Klary E Niezen-Koning2,3, Conny Bosgraaf-de Boer2,3, Albert Gerding2,3,
Dirk-Jan Reijngoud2,3 and Terry GJ Derks1,3Abstract
Background: Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is the most common inherited disorder of
the mitochondrial fatty acid oxidation, caused by mutations in the ACADM gene. Since the introduction of neonatal
screening for MCAD deficiency, a subgroup of newborns have been identified with variant ACADM genotypes that
had never been identified before in clinically ascertained patients. In vitro residual MCAD enzyme activity has been
found to facilitate risk-stratification. In this study we integrated results of in vitro (residual MCAD enzyme activities)
and in vivo (clinical fasting tolerance tests, and phenylpropionic acid loading tests) tests in this subgroup of
newborns, defining the consequences of variant ACADM genotypes.
Methods: Enzyme analyses were performed in leukocytes with: hexanoyl-CoA (C6-CoA) +/− butyryl-CoA (C4-CoA),
and phenylpropionyl-CoA (PP-CoA). In vitro studies were performed in 9 subjects with variant ACADM genotypes,
in vivo functional tests in 6 of these subjects.
Results: Enzyme analyses with C6-CoA, C6-CoA + C4-CoA, and PP-CoA identified significantly higher residual MCAD
enzyme activities in subjects with variant ACADM genotypes when compared to patients with classical ACADM
genotypes.
After prolonged fasting (range 15–18.5 hours) no hypoglycaemia was observed. Increasing concentrations of free
fatty acids indicated lipolysis, and ketone body concentrations were sufficient for blood glucose concentrations in 5
out of 6 subjects. Phenylpropionic acid loading clearly demonstrated in vivo residual MCAD enzyme activity in all
studied subjects.
Conclusions: Subjects with variant ACADM genotypes and residual MCAD enzyme activities >10% display residual
MCAD enzyme activities in vitro and in vivo. Our findings support the hypothesis that the guidelines on maximal
duration of fasting might be abandoned in subjects with residual MCAD enzyme activities >10% under normal
conditions. An emergency regimen and parental instructions remain necessary in all subjects with MCAD deficiency,
regardless of residual MCAD enzyme activity.
Keywords: ACADM, Enzyme, Genotype, Fasting, Phenylpropionic acid* Correspondence: n.touw@umcg.nl
1Section of Metabolic Diseases, Beatrix Children’s Hospital, University of
Groningen, University Medical Centre, Groningen, The Netherlands
2Laboratory of Metabolic Diseases, Department of Laboratory Medicine,
University of Groningen, University Medical Centre, Groningen, The
Netherlands
Full list of author information is available at the end of the article
© 2013 Touw et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Touw et al. Orphanet Journal of Rare Diseases 2013, 8:43 Page 2 of 8
http://www.ojrd.com/content/8/1/43Introduction
Inherited disorders of mitochondrial fatty acid oxidation
(mFAO) are a group of acute presenting, life-threatening
disorders among which medium-chain acyl coenzyme A
dehydrogenase (MCAD [E.C.1.3.99.3; OMIM 201450])
deficiency is the most common [1]. Worldwide, popula-
tion neonatal bloodspot screening (NBS) programs have
become available for the disorder.
Before the introduction of MCAD deficiency in NBS
programs, patients presented clinically with symptoms
associated with a life-threatening hypoketotic hypo-
glycaemia, such as seizures, coma or even sudden death.
The c.985A>G missense mutation on the ACADM gene
(gene encoding MCAD, OMIM 607008) was the most
common mutation. Since the introduction in NBS pro-
grams, the spectrum of ACADM genotypes changed dra-
matically. Novel ACADM genotypes were identified in
prospectively screened asymptomatic newborns (i.e. vari-
ant ACADM genotypes), of which the clinical conse-
quences are currently unknown. In previous studies our
group and others emphasized the importance of determi-
nation of residual MCAD enzyme activity, both for diag-
nostic and prognostic purposes [2,3]. However, studies in-
tegrating laboratory (in vitro) and clinical (in vivo) data are
scarce [4].
Currently, a late evening meal is advised during the
first two years of life for patients with MCAD deficiency,
regardless of the ACADM genotype [2]. Based on
in vitro data, the necessity to treat all subjects with
MCAD deficiency similarly is debatable, in particular
with regards to the advice on maximum duration of
fasting [2]. However, in vivo fasting tolerance under con-
trolled conditions has not been studied before in this
group of subjects. It can be hypothesised that residual
MCAD enzyme activities and clinical fasting tolerance
tests reflect the in vitro and in vivo role of these variant
ACADM genotypes. In order to enable personalized care
after diagnosis, clinical fasting tolerance tests were
performed in our centre in subjects with variant ACADM
genotypes after informed consent of the parents. In this
study, we integrated data on in vitro MCAD enzyme as-
says, and in vivo functional tests from 9 subjects with vari-
ant ACADM genotypes.
Methods
The Medical Ethical Committee of the University Med-
ical Centre Groningen approved the study (METc 2011/
133). Parents agreed on participation by written in-
formed consent.
Cohort
In the Netherlands MCAD deficiency has been included
in the national population NBS program since 2007. Free
carnitine (C0), octanoylcarnitine (C8:0), decanoylcarnitine(C10:0), and the C8:0/C10:0 ratio are determined in dried
blood spots obtained from newborns 72 to 168 hours after
birth (www.rivm.nl). Clinical and laboratory follow-up is ini-
tiated within 24 hours in newborns in case of elevated C8:0
concentrations. During the pilot NBS program in 2003–
2006 the cut-off concentration for C8:0 was 0.30 μmol/l [5].
Since 2007, the cut-off concentration for C8:0 has been ≥
0.50 μmol/l [2]. Diagnosis of MCAD deficiency is made after
abnormal NBS, based on persisting abnormal metabolite
profiles, the presence of 2 mutations on the ACADM gene,
and/or residual MCAD enzyme activity <50% when mea-
sured with hexanoyl-CoA (C6-CoA) in leukocytes. Labora-
tory analysis is always performed in family members of a
proband, including all siblings.
Subjects carrying ‘variant ACADM genotypes’, who
were diagnosed at the Beatrix Children’s Hospital, UMC
Groningen, Groningen, The Netherlands between 2003–
2011 were included in our cohort. A ‘variant ACADM
genotype’ was defined as an ACADM genotype that had
not been described before in clinically ascertained pa-
tients in either The Netherlands [6] or in literature.
Maximum percentage of weight loss was calculated as
the ratio between the birth weight and the lowest weight
observed in the first neonatal period.
Enzyme analysis
Residual MCAD enzyme activity was determined in
leukocytes. Before 2007, a GC-MS based analysis using
C6-CoA +/− butyryl-CoA (C4-CoA) as substrates was
the standard in our centre [7,8]. The assay with C6-CoA
has been described extensively, and was modified for
more accurate analysis of MCAD enzyme activity and
elimination of the contribution of short-chain acyl-CoA
dehydrogenase (SCAD; OMIM 606885). In this assay
785.7 μM C4-CoA was added as a substrate, besides C6-
CoA. At least one commercially available leukocyte pel-
let (Sanquin, The Netherlands) was used as control in
each enzyme assay. Molecular analysis of the ACADM
gene was performed in all subjects with residual MCAD
activity <50% when determined with C6-CoA. Since
2007, an HPLC-based assay using 3-phenylpropionyl-CoA
(PP-CoA) as a substrate is used [5,9]. Residual enzyme
activities are expressed as a percentage from healthy
controls.
Clinical fasting tolerance tests
All clinical fasting tolerance tests were performed in the
clinical function test ward of the Beatrix Children’s Hos-
pital, UMC Groningen, according to established proto-
cols [10,11]. Hypoglycemia was defined as blood glucose
concentrations <2.6 mmol/l [12]. The fasting tolerance
test was combined with a 3-phenylpropionic acid (PPA)
loading test, where 25 mg/kg PPA was administered
orally [13]. Two portions of urine were collected du-
Table 1 Characteristics of subjects with variant ACADM genotypes during fasting tolerance tests and PPA loading tests
RESULTS FASTING TEST AND PPA LOADING TEST IN CHILDREN WITH VARIANT ACADM GENOTYPES
Case Genotype NBS MCAD activity (%) Fasting test PPA loading test













(t = 15 h)
KB
(t = 15 h)
Glc*KB
(t = 15 h)
FFA/KB
(t = 15 h)
C8:0




1 c.985A>G c.199T>C 2.85 2.3 Normal 39 36 - - - - - - - - - -
2 c.985A>G c.199T>C 0.67 2.7 DC, HG 44 29 58 - - - - - - - - -
3 c.985A>G c.199T>C 0.35 2.3 Trace N-HG, SG,
DC
48 43 48 - - - - - - - - -
4 c.985A>G c.199T>C 0.74 2.8 Trace HG 36 34 44 10 18 4.5 1.1 5.0 1.0 3.7 3.4 Trace
5 c.985A>G c.473A>G 0.39 2.3 Normal 38 25 39 6 18.5 2.8 0.3 0.8 2.2 2.0 3.8 Absent
6 c.985A>G c.734C>T 1.41 3.0 Trace DC, 5-OH-C,
HG, SG
41 17 11 13 17 4.4 0.8 3.3 1.9 3.6 4.2 Trace
7 c.985A>G c.928G>A 2.28 3.2 5-OH-H, trace HG 48 23 0 16 15 3.2 3.5 10.6 - 1.9 2.9 Absent
8 c.985A>G Not
found
0.70 1.3 Normal 28 - - 25 18.5 4.0 0.9 3.7 1.5 2.9 2.1 Trace
9 c.985A>G Not
found
0.50 0.8 Normal 15 11 86 27 16.5 2.9 1.4 5.8 0.8 0.5 2.2 Trace
* Classical ACADM
genotype
2.98 12.7 5-OH-H, HG, PPG,
SG, DC
28 14 0 - 17-24 3.1 0.6 5.7 2.2 - - High


















MCAD activity is determined in leukocytes. Residual MCAD enzyme activities are depicted as percentage from controls. At least one control was included in each enzyme assay. Ref, reference value; -, not determined;
DC, dicarboxylic acids; Glc, glucose; HG, N-hexanoylglycine; SG, N-suberylglycine; PPG, phenylpropionylglycine; 5-OH-C, 5-OH-capronic acid; 5-OH-H, 5-OH-hexanoic acid; PPA, phenylpropionic acid; KB, ketone bodies;
FFA, free fatty acids. * Characteristics of patients with classical ACADM genotypes during fasting according to Bonnefont et al. [10], median values are depicted. For NBS and enzymatic data median values from the



















Touw et al. Orphanet Journal of Rare Diseases 2013, 8:43 Page 4 of 8
http://www.ojrd.com/content/8/1/43ring the fasting tolerance test. Portion 1 was obtained
after overnight fasting in the first 4 hours following PPA
loading; the second portion was obtained in the follow-
ing 4 hours of the fasting tolerance test. All PPA loading
tests were performed after the age of 6 months [14].
Urinary phenylpropionylglycine was determined by gas-
chromatography-mass spectrometry (GC-MS), according
to Chalmers et al. [15].
Data analysis
Clinical and laboratory data, and data from functional
tests were retrospectively retrieved from the medical
charts and laboratory files of the subjects by one investi-
gator (CT).
Differences between normally distributed continuous
data were analysed using parametric tests. Data that were
not normally distributed were analysed using nonparamet-
ric tests. For analysis of correlations, Spearman’s rank test
was used. The significance level was set at p < 0.05. Statis-
tical analyses were performed using GraphPad Prism soft-
ware (GraphPad Software Inc., version 5.00, 2007).
Results
Cohort
From the birth cohort 2003–2011, 50 newborns were di-
agnosed with MCAD deficiency in our centre after refer-
ral for a positive NBS (in either the pilot screeningFigure 1 Residual MCAD enzyme activities measured with different su
measured with C6-CoA; B: Residual MCAD enzyme activities measured with
PP-CoA; D: MCAD enzyme activity with PP-CoA correlates with the effect o
C6-CoA is set at 100% on the y-axis. Residual MCAD enzyme activities are d
included in each enzyme assay. Medians are indicated. * p<0.05; ** p<0.00program, or the regular nationwide NBS). In 9 of these
50 subjects (18%) a variant ACADM genotype was iden-
tified (Table 1). In two of these subjects (cases 8 & 9),
only one ACADM mutation was detected after sequen-
cing of all exons and adjacent introns. However,
acylcarnitine profiles in these subjects were indicative of
MCAD deficiency, and residual MCAD enzyme activities
were <50% when measured with C6-CoA.
Two subjects (cases 3 & 5) were diagnosed with C8:0
concentrations below 0.50 μmol/l. Case 3 was the youn-
ger sister of case 2, carrying the c.985A>G/c.199T>C
ACADM genotype. Case 5 was identified during the pilot
screening program. Maximum percentage of weight loss
in the neonatal phase in our cohort of subjects with vari-
ant ACADM genotypes correlated with C8:0 concentra-
tions upon NBS (Spearman r −0.89, p < 0.05; median
5.9%; range 4.7-9.8%). In cases 3 and 5 the maximum
percentage of weight loss was respectively 4.7% and
5.7%; in cases 8 and 9 with only one identified ACADM
mutation it was respectively 7.0% and 5.9%. None of the
subjects with a variant ACADM genotype presented clin-
ically with hypoketotic hypoglycemia, either in the neo-
natal period or after diagnosis.
In vitro studies – residual MCAD enzyme activities
Results from in vitro analyses in the 9 subjects with vari-
ant ACADM genotypes are depicted in Table 1 andbstrates in leukocytes. A: Residual MCAD enzyme activities
C6-CoA+C4-CoA; C: Residual MCAD enzyme activities measured with
f C4-CoA on C6-CoA enzyme activity. Enzyme activity measured with
epicted as percentage from controls. At least one control was
1.
Figure 2 Correlation between residual MCAD enzyme activities measured in leukocytes and C8:0/C10:0 upon NBS. A: Residual MCAD
enzyme activities measured with C6-CoA; B: Residual MCAD enzyme activities measured with C6-CoA+C4-CoA; C: Residual MCAD enzyme
activities measured with PP-CoA. Residual MCAD enzyme activities are depicted as percentage of controls. At least one control was included in
each enzyme assay. Variant ACADM genotypes are depicted as squares, classical ACADM genotypes as dots.
Figure 3 Correlation between plasma glucose and KB during
fasting tolerance test. Relationship between blood glucose and KB
concentrations is indicated. Case 5 is depicted in squares, as KB were
low for glucose concentrations. The other cases (dots) are pooled.
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were performed in leukocytes with three different sub-
strates: C6-CoA, C6-CoA + C4-CoA, and PP-CoA. Irre-
spective of the substrate, significantly higher residual
MCAD enzyme activities were measured in subjects with
variant ACADM genotypes, when compared to patients
with classical ACADM genotypes (Figure 1). However,
when measured with PP-CoA, case 7 demonstrated no
residual MCAD enzyme activity. With the natural sub-
strates C6-CoA and C6-CoA + C4-CoA, the group of
subjects with variant ACADM genotypes differed clearly
from both the group with classical ACADM genotypes,
and from carriers of the c.985A>G mutation (i.e. siblings
or parents of patients). The observed proportional change
in enzyme activity after addition of C4-CoA to the C6-
CoA assay correlated with the MCAD enzyme activity
measured with PP-CoA (Spearman r −0.72, p < 0.05)
(Figure 1D). Additionally, strong correlations were identi-
fied between residual MCAD enzyme activities measured
with PP-CoA and C6-CoA +C4-CoA, and the C8:0/C10:0
ratio identified upon NBS (Spearman r −0.65; p < 0.001
and Spearman r −0.54; p < 0.01, respectively) (Figure 2).
In vivo studies – fasting tolerance test
Clinical fasting tolerance tests were performed in 6 sub-
jects with a variant ACADM genotype, at a median age
of 14.5 months (range 6–27 months). The duration offasting was supra-physiological in all subjects, as regular
overnight fasting duration was extended. Case 7 fasted
for 15 hours and the remaining 5 subjects for 16.5 –
18.5 hours (Table 1). Concentrations of glucose, free
fatty acids (FFA), ketone bodies (KB), and their ratios
after 15 hours of fasting are depicted in Table 1. All sub-
jects could complete the fasting tolerance tests without
clinical symptoms and/or hypoglycaemia.
Case 5 demonstrated normal fasting parameters after
overnight fasting but hypoketosis after 18.5 hours. Low
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time reflected a minimal role of mFAO under these cir-
cumstances in this subject, with subsequent low concen-
trations of KB (squares in Figure 3) [10,11].
Case 7 and case 9 also showed blood glucose concentra-
tions that were below p10 for age and duration of fasting
after 15 hours of fasting. FFA/KB ratios were at p10 for
age and duration of fasting, with increasing concentrations
of FFA and KB around p90. All other included subjects
had KB concentrations that corresponded to blood glu-
cose concentrations upon fasting (dots in Figure 3C).
A relationship between biochemical response to fas-
ting and residual MCAD enzyme activity with either
substrate could not be identified.
During fasting, C8:0 concentrations increased in time.
Additionally, observed concentrations during fasting
were considerably higher when compared to the concen-
trations that were seen during regular visits to the out-
patient clinic (median during follow-up 0.6 umol/l;
median after 15 h fasting 3.2 umol/l, p = 0.07). C8:0 con-
centrations during fasting did not correlate with concen-
trations found in the initial NBS test.
The C8:0/C2:0 and C8:0/C10:0 ratios during fasting
were slightly higher than the ratios that were identified
upon NBS and during regular visits to the outpatient
clinic (Table 1). During the fasting tolerance test the ra-
tios remained stable in time in all subjects [16].
In case 8, longer-chain acylcarnitines accumulated in
time, besides medium-chain acylcarnitines (acylcarnitines
after 18.5 hours of fasting: C12:0 0.60 μmol/l, C14:0 0.23 -
μmol/l, C14:1 0.75 μmol/l).
Prolonged fasting was associated with increasingly ab-
normal excretion patterns of organic acids, with N-
hexanoylglycine, and dicarboxylic acids in the urine of
all subjects with variant ACADM genotypes during
fasting, as opposed to the observations during regular
visits to the outpatient clinic, when few or no abnormal
metabolites were be detected.
PPA loading test
The fasting tests were combined with a PPA loading test.
After oral administration of PPA, no phenylpropionylglycine
(PP-glycine) or trace amounts were excreted in the urine,
together with large amounts of hippuric acid.
Discussion
Since the introduction of NBS for MCAD deficiency, a
new subgroup of newborns has been identified with vari-
ant ACADM genotypes that have not been seen before
in clinically ascertained patients with classical ACADM
genotypes. It remains unclear whether subjects with
these variant ACADM genotypes are at risk for the
development of a clinical phenotype. Prevention of
prolonged fasting was found to be debatable whenMCAD enzyme activities >10% were measured with PP-
CoA [2]. In the current study, additional support was
provided to abandon the advice on prevention of
prolonged fasting under normal conditions in subjects
with residual MCAD enzyme activities >10%. All in-
cluded subjects could tolerate an overnight controlled
fasting tolerance test for at least 15 hours under healthy
conditions. An additional PPA loading test determined
in vivo residual MCAD enzyme activity. These func-
tional tests were performed after the age of 6 months in
all cases, when weaning naturally occurs and PPA load-
ing tests can be performed reliably [14].
Several factors cause diversity between the subjects
with variant ACADM genotypes that have been identi-
fied since introduction of NBS. Firstly, different ACADM
genotypes are represented in this group. Secondly, the
NBS protocol has been adapted in 2007, and has thus
not been similar for all included subjects. Thirdly, treat-
ment in the newborn period has not been the same in
all subjects in this group. Identification of affected new-
born siblings of probands was associated with dietary in-
terventions from birth onwards in this group, instead of
starting after positive NBS results.
Interestingly, two cases (case 3 and case 5) were identi-
fied upon NBS with C8:0 concentrations below the
current cut-off concentration of 0.50 μmol/l, despite
ACADM mutations on both alleles. Case 3 was identified
upon family screening and case 5 during the pilot NBS
program. With the elevation of the C8:0 cut-off concentra-
tion in 2007, the national criteria for subjects who should
be regarded “patients” have also been adapted. However,
due to family screening we still identify subjects with
ACADM mutations on both alleles, but C8:0 concentra-
tions below the cut-off value. How can we interpret these
observations? C8:0 concentrations in newborns can theo-
retically be influenced by nutritional state [5], prematurity
and/or very low birth weight [17], heterozygosity for the
c.985A>G mutation [18], and the time at which NBS is
performed [19]. In our cohort, nutritional state can have
affected NBS C8:0 concentrations, as these concentrations
clearly correlated with percentage of maximum weight
loss in the neonatal phase. Except for case 3, all subjects
with a variant ACADM genotype in our cohort were first-
borns who were breastfed. With breastfeeding caloric in-
take cannot be monitored, as opposed to during formula
feeding. Especially in firstborns onset of lactation can be
delayed, leading to suboptimal food intake in the first days
of life [20]. Catabolism and subsequent increase in C8:0
concentrations can result from this. In case 3, C8:0 con-
centrations may have remained <0.50 μmol/l due to the
positive family history and subsequent frequent feeding
regimen that was started at birth.
Two subjects in our study (case 8 and case 9)
displayed only one ACADM mutation after sequencing
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identified upon NBS, as heterozygotes are usually not
identified with the current C8:0 cut-off concentration
[18]? Case 8 and case 9 were not considered normal
false-positives, and where included in the cohort based
on the combination of (1) persisting abnormal plasma
and urinary metabolites, and (2) residual MCAD enzyme
activity determined with C6-CoA. Results from fasting
tolerance tests were remarkable in both subjects. In case
8, acylcarnitines with increasing chain-lengths up to
C16:0 accumulated upon fasting. The C8:0 concentra-
tion increased considerably to a maximum of 4.7 μmol/l,
whereas the C8:0/C10:0 remained <2.5. Theoretically,
these findings may indicate another phenotype-
modifying mutation on a gene that plays a role in
mFAO, a phenomenon known as synergistic heterozy-
gosity [21,22]. Vockley et al. described the concept of
synergistic heterozygosity, i.e. multiple partial defects in
more than one metabolic pathway, leading to clinical
symptoms that correlate with the affected pathways [22].
In combination with the classical c.985A>G ACADM
mutation, theoretical candidate genes to cause accumu-
lation of acylcarnitines with medium and long chain-
length are ETFA (HGNC:3481), ETFB (HGNC:3482),
ETFDH (HGNC:3483), ACADS (HGNC:90) or ACADVL
(HGNC:92) especially during episodes with increased
catabolic stress such as during prolonged fasting. In case
8, C14:1 concentrations increased to a maximum of
0.75 μmol/l upon prolonged fasting, with a correspond-
ing C14:1/C16:0 ratio of 4.4. The interpretation of these
findings is complicated as, currently, no paediatric refer-
ence values for acylcarnitines during prolonged fasting
are available. In case 9, the in vivo and in vitro observa-
tions might be explained by other molecular mecha-
nisms (e.g. deep-intronic mutations, mutations in the
promoter region, and deletion/duplication mutations)
that can be missed upon gene sequencing, next to syner-
gistic heterozygosity [23,24].
We observed a normal fasting tolerance in subjects
with variant ACADM genotypes and residual MCAD en-
zyme activities >10% under normal conditions after the
age of 6 months. Based on these results, the need to pre-
scribe a standard late evening meal in these subjects is
debatable. PPA loading tests cannot be reliably
performed before the age of 6 months [14]. As PPA
loading tests were in this study combined with the
fasting tolerance tests, no data are currently available on
fasting tolerance in subjects with variant ACADM geno-
types and residual MCAD enzyme activities >10% before
the age of 6 months. It is well known that even patients
with classical ACADM genotypes can tolerate overnight
fasting already at a young age [6,25]. Besides, stable iso-
tope studies demonstrated normal FFA and KB metabol-
ism in patients with classical ACADM genotypes [26,27].Administration of a late evening meal has several disad-
vantages: First of all, it can be considered a burden for
both parents and the child, especially in the first year of
life when the maximum duration of fasting is 6–8 hours
[28]. Additionally, administration of a late evening meal
increases the risks on overfeeding and dental caries
[6,29]. In our opinion, abovementioned arguments, com-
bined with the current data, justify abolishing a standard
late evening meal in subjects with variant ACADM geno-
types and residual MCAD enzyme activities >10% after
the age of 6 months. In vivo functional tests can facilitate
development of individualized patient-based guidelines for
follow-up reliably from the age of 6 months. However,
until the pathophysiology of MCAD deficiency and its var-
iants is unravelled, an emergency regimen and parental in-
structions remain indispensable in the follow-up of all
subjects with a positive NBS for MCAD deficiency.
Conclusions
Variant ACADM genotypes with residual MCAD en-
zyme activities >10% in vitro are associated with normal
residual MCAD enzyme activities in vivo (defined by
PPA loading) and normal fasting tolerance. The general
advice to prevent prolonged fasting can be abolished in
subjects with residual MCAD enzyme activities >10%
after the age of 6 months. However, an emergency regi-
men and parental instructions remain necessary in all
subjects with MCAD deficiency, regardless of residual
MCAD enzyme activity, at least until the pathophysi-
ology of MCAD deficiency has been elucidated.
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